Dr. Richard Harold Haubrich, MD

This physician's panel is closed to new HMO members enrolling with this physician for the first time.Richard H. Haubrich, M.D. is a Professor of Medicine in the Department of Medicine, Division of Infectious Diseases, at the University of California, San Diego (UCSD). Since joining the UCSD faculty in 1991, Dr. Haubrich has focused on clinical research related to antiretroviral therapy and the medical management of HIV-infected patients. In 2003, he became the overall Principal Investigator of the California Collaborative Treatment Group, a consortium of clinical investigators at five California medical schools or affiliates. Dr. Haubrich is also an active investigator AIDS Clinical Trials Group (ACTG), and is currently the Vice-Chair of the ACTG Optimization of Antiretroviral Therapy Committee. Dr. Haubrich is Co-Director of the UCSD CFAR Clinical Investigation Core.

Dr. Haubrich has participated in numerous clinical trials that include novel antiretroviral therapies, combination …antiretroviral therapy, clinical strategy trials of HIV technologies, and the utility of HIV phenotype resistance in the management of antiretroviral therapy. Dr. Haubrich’s current research focuses on antiretroviral therapy for treatment-naive and treatment-experienced patients, HIV drug resistance, and pharmacology of antiretroviral agents. He is co-chair of ACTG 5142, an international, 753-patient randomized clinical trial of three therapies for treatment-naive patients and vice-chair of the ACTG OPTIONS study which will evaluate new treatment paradigms for highly antiretroviral-experienced patients.

Dr. Haubrich has published extensively in peer-reviewed journals including AIDS, The Journal of Infectious Diseases, The Journal of Acquired Immune Deficiency Syndromes (JAIDS), Clinical Infectious Diseases, and Antiviral Therapy. He has been invited to present his work at numerous international meetings, including the International AIDS Conference, the Conference on Retroviruses and Opportunistic Infections, the International HIV Drug Resistance Workshop, the IAS-USA and the Infectious Diseases Society of America.